Company · intermune-da29d705

InterMune

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. InterMune. Companies, record intermune-da29d705. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/intermune-da29d705

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: InterMune
Trials: 23
As lead sponsor: 15
As collaborator: 8
Recruiting: 0
Active, recruiting or not: 0
Completed: 15
Stopped early, withdrawn or suspended: 6
Posted results: 3
Trials by phase: Phase 1 3, Phase 2 13, Phase 3 6, Phase 4 2
Drugs its trials test: 15
Comparisons calculated in its trials: 2
First trial registered: 2001-08-31
Last update: 2016-06-13

Source ClinicalTrials.gov

Pipeline15

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	As lead sponsor	Targets	Mechanism	In Drugs and targets	Source
RIBAVIRIN	Phase 4	4	1	IMPDH1	Inosine-5'-monophosphate dehydrogenase 1 inhibitor	https://conductscience.org/library/drugs/CHEMBL1643	Open Targets
INTERFERON ALFACON-1	Phase 4	1	0	IFNAR1, IFNAR2	Interferon alpha/beta receptor agonist	https://conductscience.org/library/drugs/CHEMBL1201557	Open Targets
ROSIGLITAZONE	Phase 4	1	0	PPARG	Peroxisome proliferator-activated receptor gamma agonist	https://conductscience.org/library/drugs/CHEMBL121	Open Targets
INTERFERON GAMMA-1B	Phase 3	18	15	IFNGR1, IFNGR2	Interferon gamma receptor agonist	https://conductscience.org/library/drugs/CHEMBL1201564	Open Targets
CARBOPLATIN	Phase 3	2	1			https://conductscience.org/library/drugs/CHEMBL1351	Open Targets
AZATHIOPRINE	Phase 3	1	1	PPAT	Amidophosphoribosyltransferase inhibitor	https://conductscience.org/library/drugs/CHEMBL1542	Open Targets
PACLITAXEL	Phase 3	1	1	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	Tubulin inhibitor	https://conductscience.org/library/drugs/CHEMBL428647	Open Targets
ADEFOVIR DIPIVOXIL	Phase 2	1	0			https://conductscience.org/library/drugs/CHEMBL922	Open Targets
BEVACIZUMAB	Phase 2	1	0	VEGFA	Vascular endothelial growth factor A inhibitor	https://conductscience.org/library/drugs/CHEMBL1201583	Open Targets
FLUCONAZOLE	Phase 2	1	1			https://conductscience.org/library/drugs/CHEMBL106	Open Targets

1 to 10 of 15

See all 15 pipeline

Trials23

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	Results first posted	Drugs	In Trials	Source
NCT02176707	Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis	Collaborator		Unknown status	Observational	250	2014-06			https://conductscience.org/library/trials/NCT02176707	ClinicalTrials.gov
NCT00786643	Study of Gamma Interfereon in Metastatic Colorectal Carcinoma	Collaborator	Phase 2	Completed	Interventional	48	2006-02	2012-02-22	BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN	https://conductscience.org/library/trials/NCT00786643	ClinicalTrials.gov
NCT00753467	A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B	Collaborator	Phase 2	Unknown status	Interventional	30	2008-09		ADEFOVIR DIPIVOXIL, INTERFERON GAMMA-1B	https://conductscience.org/library/trials/NCT00753467	ClinicalTrials.gov
NCT00501644	Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer	Collaborator	Phase 2	Completed	Interventional	59	2003-01	2011-01-10	CARBOPLATIN, INTERFERON GAMMA-1B, REGRAMOSTIM	https://conductscience.org/library/trials/NCT00501644	ClinicalTrials.gov
NCT00266318	Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy	Collaborator	Phase 4	Completed	Interventional	40	2005-12		INTERFERON ALFACON-1, RIBAVIRIN	https://conductscience.org/library/trials/NCT00266318	ClinicalTrials.gov
NCT00211692	Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial	Collaborator	Phase 3	Completed	Interventional	64	2005-07	2014-11-21	RIBAVIRIN	https://conductscience.org/library/trials/NCT00211692	ClinicalTrials.gov
NCT00207402	Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin	Collaborator	Phase 4	Completed	Interventional	34	2005-10		ROSIGLITAZONE	https://conductscience.org/library/trials/NCT00207402	ClinicalTrials.gov
NCT00148863	Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C	Collaborator	Phase 2	Completed	Interventional	65	2004-06		INTERFERON GAMMA-1B, RIBAVIRIN	https://conductscience.org/library/trials/NCT00148863	ClinicalTrials.gov
NCT00084279	CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)	Lead sponsor	Phase 2	Completed	Interventional	81	2004-04		INTERFERON GAMMA-1B, RIBAVIRIN	https://conductscience.org/library/trials/NCT00084279	ClinicalTrials.gov
NCT00076635	An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF	Lead sponsor	Phase 3	Terminated	Interventional	91	2003-11		INTERFERON GAMMA-1B	https://conductscience.org/library/trials/NCT00076635	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Conditions24

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Idiopathic Pulmonary Fibrosis	5
Lung Disease	4
Pulmonary Fibrosis	4
Chronic Hepatitis C	2
Cystic Fibrosis	2
Hepatitis C	2
Anxiety	1
Cirrhosis	1
Colorectal Cancer	1
Depression	1

1 to 10 of 24Source ClinicalTrials.gov

See all 24 conditions

Partners15

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Accelerated Community Oncology Research Network	Other	1		ClinicalTrials.gov
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma	Industry	1	https://conductscience.org/library/companies/bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma-9cb0a505	ClinicalTrials.gov
Beth Israel Medical Center	Other	1		ClinicalTrials.gov
Bristol-Myers Squibb	Industry	1	https://conductscience.org/library/companies/bristol-myers-squibb-1255780f	ClinicalTrials.gov
Brooke Army Medical Center	US federal	1		ClinicalTrials.gov
Center for Veterans Research and Education	Other	1		ClinicalTrials.gov
French National Agency for Research on AIDS and Viral Hepatitis	Other government	1		ClinicalTrials.gov
Hoffmann-La Roche	Industry	1	https://conductscience.org/library/companies/hoffmann-la-roche-8af6ddcd	ClinicalTrials.gov
Huntington Medical Research Institutes	Other	1		ClinicalTrials.gov
Kadmon Corporation, LLC	Industry	1	https://conductscience.org/library/companies/kadmon-corporation-llc-4e28cab5	ClinicalTrials.gov

1 to 10 of 15

See all 15 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/intermune-da29d705

GET https://conductscience.org/api/companies/v1/intermune-da29d705/trials?page=2

API reference For AI assistants